Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 290

1.

Unique human tumor antigens: immunobiology and use in clinical trials.

Parmiani G, De Filippo A, Novellino L, Castelli C.

J Immunol. 2007 Feb 15;178(4):1975-9. Review.

2.

Tumor antigens as surrogate markers and targets for therapy and vaccines.

Dalgleish A, Pandha H.

Adv Cancer Res. 2007;96:175-90. Review.

PMID:
17161680
3.

Cancer immunotherapy targeting the telomerase reverse transcriptase.

Huo LF, Tang JW, Huang JJ, Huang PT, Huang CF, Kung HF, Lin MC.

Cell Mol Immunol. 2006 Feb;3(1):1-11. Review.

4.

Development of vaccines against self-antigens: the p53 paradigm.

Chada S, Mhashilkar A, Roth JA, Gabrilovich D.

Curr Opin Drug Discov Devel. 2003 Mar;6(2):169-73. Review.

PMID:
12669451
5.

Antitumor vaccination using peptide based vaccines.

Eisenbach L, Bar-Haim E, El-Shami K.

Immunol Lett. 2000 Sep 15;74(1):27-34. Review.

PMID:
10996624
6.

Tumor-specific antigens and immunologic adjuvants in cancer immunotherapy.

Seremet T, Brasseur F, Coulie PG.

Cancer J. 2011 Sep-Oct;17(5):325-30. doi: 10.1097/PPO.0b013e3182326004. Review.

PMID:
21952282
7.

New frontiers in cell-based immunotherapy of cancer.

D'Elios MM, Del Prete G, Amedei A.

Expert Opin Ther Pat. 2009 May;19(5):623-41. doi: 10.1517/13543770902817820. Review.

PMID:
19441938
8.

Current state of vaccine therapies in non-small-cell lung cancer.

Romero P.

Clin Lung Cancer. 2008 Feb;9 Suppl 1:S28-36. Review.

PMID:
18540532
9.

Targets for active immunotherapy against pediatric solid tumors.

Jacobs JF, Coulie PG, Figdor CG, Adema GJ, de Vries IJ, Hoogerbrugge PM.

Cancer Immunol Immunother. 2009 Jun;58(6):831-41. doi: 10.1007/s00262-008-0619-x. Epub 2008 Nov 14. Review.

PMID:
19009292
10.

Recent developments in therapeutic cancer vaccines.

Morse MA, Chui S, Hobeika A, Lyerly HK, Clay T.

Nat Clin Pract Oncol. 2005 Feb;2(2):108-13. Review.

PMID:
16264883
11.

Cancer vaccines: reborn or just recycled?

Berd D.

Semin Oncol. 1998 Dec;25(6):605-10. Review.

PMID:
9865675
12.

Immunology and immunotherapy of human cancer: present concepts and clinical developments.

Bremers AJ, Parmiani G.

Crit Rev Oncol Hematol. 2000 Apr;34(1):1-25. Review.

PMID:
10781746
13.

Therapeutic cancer vaccines: using unique antigens.

Lewis JJ.

Proc Natl Acad Sci U S A. 2004 Oct 5;101 Suppl 2:14653-6. Epub 2004 Aug 5. Review.

14.

Randomized clinical studies of anti-tumor vaccination: state of the art in 2008.

Fournier P, Schirrmacher V.

Expert Rev Vaccines. 2009 Jan;8(1):51-66. doi: 10.1586/14760584.8.1.51. Review.

PMID:
19093773
15.

Cancer vaccines in phase II/III clinical trials: state of the art and future perspectives.

Cecco S, Muraro E, Giacomin E, Martorelli D, Lazzarini R, Baldo P, Dolcetti R.

Curr Cancer Drug Targets. 2011 Jan;11(1):85-102. Review.

PMID:
21062241
16.

[Current status and future perspective of cancer vaccine development].

Sasada T, Itoh K.

Gan To Kagaku Ryoho. 2011 Apr;38(4):503-8. Review. Japanese.

PMID:
21498975
17.

Paradigm shifts in cancer vaccine therapy.

Schlom J, Gulley JL, Arlen PM.

Exp Biol Med (Maywood). 2008 May;233(5):522-34. doi: 10.3181/0708-MR-226. Epub 2008 Mar 28. Review.

PMID:
18375829
18.
19.

Immunology and breast cancer: therapeutic cancer vaccines.

Curigliano G, Rescigno M, Goldhirsch A.

Breast. 2007 Dec;16 Suppl 2:S20-6. Epub 2007 Aug 13. Review.

PMID:
17706425
20.

WT1 peptide vaccine as a paradigm for "cancer antigen-derived peptide"-based immunotherapy for malignancies: successful induction of anti-cancer effect by vaccination with a single kind of WT1 peptide.

Oka Y, Tsuboi A, Fujiki F, Li Z, Nakajima H, Hosen N, Shirakata T, Nishida S, Oji Y, Kawase I, Sugiyama H.

Anticancer Agents Med Chem. 2009 Sep;9(7):787-97. Epub 2009 Sep 1. Review.

PMID:
19538172

Supplemental Content

Support Center